The immunoglobulin A IgA vasculitis market size has shown solid growth in recent years, escalating from $1.53 billion in 2024 to $1.63 billion in 2025, indicating a compound annual growth rate CAGR of ...

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune ...

The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

Prince Edward Island’s Chief Public Health Office says a total of 15 people have now been identified as at risk after ...

It is the only ready-to-use liquid immunoglobulin therapy with (IgA) content and is set for commercialization in 2026.

In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection ...

Prince Edward Island's Chief Public Health Office has now identified 10 infants who require medication to protect them ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process ...

ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.

The U.S. Intravenous Immunoglobulin Market plays a crucial role in treating immunodeficiency diseases and various autoimmune disorders, reflecting a steady evolution influenced by advanced therapies ...